These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36038111)

  • 21. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
    Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
    Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples.
    Morden CR; Farrell AC; Sliwowski M; Lichtensztejn Z; Altman AD; Nachtigal MW; McManus KJ
    Gynecol Oncol; 2021 Jun; 161(3):769-778. PubMed ID: 33714608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
    Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L
    J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor specific methylome in Chinese high-grade serous ovarian cancer characterized by gene expression profile and tumor genotype.
    Song F; Li L; Zhang B; Zhao Y; Zheng H; Yang M; Li X; Tian J; Huang C; Liu L; Wang Q; Zhang W; Chen K
    Gynecol Oncol; 2020 Jul; 158(1):178-187. PubMed ID: 32362568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach.
    Garziera M; Roncato R; Montico M; De Mattia E; Gagno S; Poletto E; Scalone S; Canzonieri V; Giorda G; Sorio R; Cecchin E; Toffoli G
    Cells; 2019 Jun; 8(6):. PubMed ID: 31197119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomic Characterization of High-Grade Serous Ovarian Cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies.
    Mittempergher L
    Curr Oncol Rep; 2016 Jul; 18(7):44. PubMed ID: 27241520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The high-grade serous ovarian cancer metastasis and chemoresistance in 3D models.
    Tadić V; Zhang W; Brozovic A
    Biochim Biophys Acta Rev Cancer; 2024 Jan; 1879(1):189052. PubMed ID: 38097143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling.
    Bashashati A; Ha G; Tone A; Ding J; Prentice LM; Roth A; Rosner J; Shumansky K; Kalloger S; Senz J; Yang W; McConechy M; Melnyk N; Anglesio M; Luk MT; Tse K; Zeng T; Moore R; Zhao Y; Marra MA; Gilks B; Yip S; Huntsman DG; McAlpine JN; Shah SP
    J Pathol; 2013 Sep; 231(1):21-34. PubMed ID: 23780408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular Management of High-Grade Serous Ovarian Carcinoma.
    Punzón-Jiménez P; Lago V; Domingo S; Simón C; Mas A
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence for the antagonistic form of CXC-motif chemokine CXCL10 in serous epithelial ovarian tumours.
    Rainczuk A; Rao JR; Gathercole JL; Fairweather NJ; Chu S; Masadah R; Jobling TW; Deb-Choudhury S; Dyer J; Stephens AN
    Int J Cancer; 2014 Feb; 134(3):530-41. PubMed ID: 23873303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Search for New Participants in the Pathogenesis of High-Grade Serous Ovarian Cancer with the Potential to Be Used as Diagnostic Molecules.
    Timofeeva AV; Asaturova AV; Sannikova MV; Khabas GN; Chagovets VV; Fedorov IS; Frankevich VE; Sukhikh GT
    Life (Basel); 2022 Dec; 12(12):. PubMed ID: 36556382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumour microenvironment-based molecular profiling reveals ideal candidates for high-grade serous ovarian cancer immunotherapy.
    Lu X; Ji C; Jiang L; Zhu Y; Zhou Y; Meng J; Gao J; Lu T; Ye J; Yan F
    Cell Prolif; 2021 Mar; 54(3):e12979. PubMed ID: 33522069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiomic Analysis of Subtype Evolution and Heterogeneity in High-Grade Serous Ovarian Carcinoma.
    Geistlinger L; Oh S; Ramos M; Schiffer L; LaRue RS; Henzler CM; Munro SA; Daughters C; Nelson AC; Winterhoff BJ; Chang Z; Talukdar S; Shetty M; Mullany SA; Morgan M; Parmigiani G; Birrer MJ; Qin LX; Riester M; Starr TK; Waldron L
    Cancer Res; 2020 Oct; 80(20):4335-4345. PubMed ID: 32747365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome.
    Vargas HA; Veeraraghavan H; Micco M; Nougaret S; Lakhman Y; Meier AA; Sosa R; Soslow RA; Levine DA; Weigelt B; Aghajanian C; Hricak H; Deasy J; Snyder A; Sala E
    Eur Radiol; 2017 Sep; 27(9):3991-4001. PubMed ID: 28289945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
    El-Arabey AA; Denizli M; Kanlikilicer P; Bayraktar R; Ivan C; Rashed M; Kabil N; Ozpolat B; Calin GA; Salama SA; Abd-Allah AR; Sood AK; Lopez-Berestein G
    Cell Signal; 2020 Apr; 68():109539. PubMed ID: 31935430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical characteristics and outcomes of cases with pure ovarian clear cell, mixed type and high-grade serous adenocarcinoma.
    Kucukgoz Gulec U; Paydas S; Guzel AB; Vardar MA; Khatib G; Gumurdulu D
    Arch Gynecol Obstet; 2015 Oct; 292(4):923-9. PubMed ID: 25855053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences between complex epithelial neoplasms of the ovary and high-grade serous ovarian cancer: a retrospective observational cohort study.
    Li X; Ding Y; Liu Y; Yang M
    J Ovarian Res; 2022 Dec; 15(1):125. PubMed ID: 36456989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
    Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Ganapathi RN; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI
    Eur J Cancer; 2017 Jul; 79():214-225. PubMed ID: 28525846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ACSM3 suppresses the pathogenesis of high-grade serous ovarian carcinoma via promoting AMPK activity.
    Yang X; Wu G; Zhang Q; Chen X; Li J; Han Q; Yang L; Wang C; Huang M; Li Y; Chen J; LiLi ; Wang H; Liu K
    Cell Oncol (Dordr); 2022 Feb; 45(1):151-161. PubMed ID: 35124784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intraindividual genomic heterogeneity of high-grade serous carcinoma of the ovary and clinical utility of ascitic cancer cells for mutation profiling.
    Choi YJ; Rhee JK; Hur SY; Kim MS; Lee SH; Chung YJ; Kim TM; Lee SH
    J Pathol; 2017 Jan; 241(1):57-66. PubMed ID: 27741368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.